clinical trials

All too often, older patients are given drugs and other therapies that have not been tested on people beyond a certain age
An experimental treatment for Alzheimer's disease has turned out to be a disappointment in the first finished late-stage study, manufacturer Pfizer said Monday. Called bapineuzumab, it's one of three Alzheimer's treatments currently in clinical trials that some have been calling our "last hope" for drugs that slow the progression of the disease.
Search AARP Blogs